{"response": {"status": "ok", "userTier": "developer", "total": 1, "content": {"id": "business/2007/nov/20/1", "type": "article", "sectionId": "business", "sectionName": "Business", "webPublicationDate": "2007-11-20T23:50:56Z", "webTitle": "Business news in brief", "webUrl": "https://www.theguardian.com/business/2007/nov/20/1", "apiUrl": "https://content.guardianapis.com/business/2007/nov/20/1", "fields": {"headline": "News in brief", "bodyText": "US leukaemia specialists agree $2.9bn merger Two leading US developers of drugs for blood cancer are coming together through a $2.9bn (\u00a31.42bn) takeover of Pharmion by its larger biotechnology rival Celgene. The deal will combine their sales forces, strengthening international marketing and bolstering their presence in Europe. Colorado-based Pharmion has grown rapidly, fuelled by strong sales of its leukaemia drug, Vidaza. Celgene is renowned for reviving the drug thalidomide, which caused birth defects in the 1950s and 60s, Sold as Thalomid, Celgene's version is a treatment for leprosy and multiple myeloma. Andrew Clark in New York Corporate jet passengers are given safety warning The aviation industry watchdog is warning corporate jet passengers to check the safety credentials of their operator before taking an executive flight. The Civil Aviation Authority launched a marketing campaign yesterday urging travellers to ensure that the company they are flying with has an air operator's certificate. It has prosecuted four operators over the past five years for carrying passengers without an AOC and its leaflet warns against \"unscrupulous operators who choose to circumvent the system\". It said taking an illegal flight could invalidate some passengers' life insurance policies. Dan Milmo"}, "isHosted": false, "pillarId": "pillar/news", "pillarName": "News"}}}